Downregulation and prognostic performance of microRNA 224 expression in prostate cancer

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 261-269

  Mavridis, Konstantinos ^a   Stravodimos, Konstantinos ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MICRORNA; MICRORNA 224; POLYNUCLEOTIDE ADENYLYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; POLYADENYLATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; TRANSURETHRAL RESECTION;

BASE SEQUENCE; DNA PRIMERS; DOWN-REGULATION; HUMANS; MALE; MICRORNAS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872035173     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.191502     Document Type: Article

References (40)

1. Diamandis EP. Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion? Clin Chem 2010;56:345-51.
2. Wheeler DC, Szymanski KM, Black A, Nelson DE. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening. BMC Cancer 2011;11:148.
3. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010;7:286-97.
4. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, et al. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol 2011;39:1183-92.
5. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, et al. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol 2010;28:4-13.
6. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006;25:6188-96.
7. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166-76.
8. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
9. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707.
10. Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with ret status and outcome. Thyroid 2012;22:890-6.
11. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010;11:50-4.
12. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, et al. HSA-MIR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 2012;226:108-19.
13. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010;23:1229-34.
14. Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, et al. Involvement of CD40 targeting MIR-224 and MIR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009;16:2339-50.
15. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 2010;4:51.
16. Boguslawska J, Wojcicka A, Piekielko-Witkowska A, Master A, Nauman A. MIR-224 targets the 3′UTR of type 1 5′-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS One 2011;6:e24541.
17. Fellenberg J, Saehr H, Lehner B, Depeweg D. A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. Cancer Lett 2012;321:162-8.
18. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008;105:15535-40.
19. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008;68:1152-64.
20. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011;6:e18286.
21. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008;283:13205-15.
22. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small noncoding RNA transcriptome in prostate cancer. Oncogene 2012;31:978-91.
23. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011;32:772-8.
24. Nonn L, Vaishnav A, Gallagher L, Gann PH. mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp Mol Pathol 2010;88:45-51.
25. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory role of MIR-203 in prostate cancer progression and metastasis. Clin Cancer Res 2011;17:5287-98.
26. Larne O, Edsjo A, Bjartell A, Ceder Y. Development of a miRNA assay for prostate cancer detection. Eur Urol Suppl 2009;8(Suppl):S316.
27. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
28. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS. Regulation of miRNA expression by SRC and contact normalization: effects on nonanchored cell growth and migration. Oncogene 2009;28:4272-83.
29. Li Q, Wang G, Shan JL, Yang ZX, Wang HZ, Feng J, et al. MicroRNA-224 is upregulated in HEPG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 2010;25:164-71.
30. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY. UBC9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010;29:1763-72.
31. White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, et al. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 2010;102:1244-53.
32. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8.
33. Mouillet JF, Chu T, Nelson DM, Mishima T, Sadovsky Y. MIR-205 silences med1 in hypoxic primary human trophoblasts. FASEB J 2010;24:2030-9.
34. Yao G, Yin M, Lian J, Tian H, Liu L, Li X, Sun F. MicroRNA-224 is involved in transforming growth factor-beta-mediated mouse granulosa cell proliferation and granulosa cell function by targeting SMAD4. Mol Endocrinol 2010;24:540-51.
35. Lichner Z, Mejia-Guerrero S, Ignacak M, Krizova A, Bao TT, Girgis AH, et al. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am J Pathol 2012;180:1675-87.
36. White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, et al. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem 2010;391:411-23.
37. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, et al. Expression of CXCR4 and CXCL12 (Sdf-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-73.
38. Gladson CL, Welch DR. New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther 2008;7:1849-51.
39. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. Going malignant: the hypoxiacancer connection in the prostate. BioEssays 2002;24:749-57.
40. Avgeris M, Mavridis K, Scorilas A. Kallikreinrelated peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem 2012;393:301-17.